CA
NZ
UK
AU
IND
US
…
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization therapy (SOLVE-CRT), an investigational device exemption. The company was incorporated in 2003 and is headquartered in Sunnyvale, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
EBR Systems is an Australian medical-device company developing implantable neuromodulation technology intended to treat chronic diseases by modulating the autonomic nervous system. Long-term growth drivers include successful clinical trial outcomes, regulatory approvals and clinical adoption across cardiology and related specialties, which could support revenue growth as population aging increases demand. The company's focused technology platform and addressable unmet clinical needs may attract investors seeking exposure to bioelectronic medicine.
Key investment risks include clinical trial setbacks, regulatory approval uncertainty and the need for additional capital to reach commercialization and scale.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -50.46M | -20.17M | -35.04M | -33.09M | -39.84M |
| Net income | -50.46M | -20.17M | -35.04M | -33.09M | -39.84M |
| Selling general administrative | - | 5.82M | 6.70M | 5.41M | 3.14M |
| Selling and marketing expenses | - | - | 6.89M | 8.11M | 6.81M |
| Gross profit | 0.51M | - | - | - | - |
| Reconciled depreciation | - | 0.97M | 0.75M | 0.65M | 0.38M |
| Ebit | -47.69M | -38.32M | -25.42M | -24.28M | -15.24M |
| Ebitda | -47.28M | -37.73M | -24.66M | -23.62M | -14.86M |
| Depreciation and amortization | 0.42M | 0.59M | 0.75M | 0.65M | 0.38M |
| Operating income | -47.69M | -38.32M | -34.55M | -24.28M | -15.24M |
| Other operating expenses | 49.37M | 19.02M | 34.55M | 27.39M | 17.57M |
| Interest expense | 5.84M | 3.00M | 4.48M | 1.53M | 19.01M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 3.18M | 3.28M | 2.46M | 0.02M |
| Net interest income | - | -2.85M | -4.48M | 0.94M | -18.99M |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M | 20.94M |
| Total revenue | 1.67M | 0.00M | 0.00M | - | 0.00M |
| Total operating expenses | 48.20M | 19.02M | 34.55M | 27.39M | 17.57M |
| Cost of revenue | 1.17M | - | - | - | - |
| Total other income expense net | -2.76M | -2.48M | -0.49M | -7.28M | -3.66M |
| Net income from continuing ops | - | -40.80M | -35.04M | -33.09M | -39.84M |
| Net income applicable to common shares | - | - | - | -33.09M | -39.84M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 97.29M | 73.56M | 78.90M | 71.68M | 85.42M |
| Other current assets | 3.82M | 1.97M | 0.38M | 0.61M | 0.17M |
| Total liab | 71.69M | 49.20M | 47.84M | 27.73M | 9.53M |
| Total stockholder equity | 25.61M | 24.36M | 31.06M | 43.95M | 75.90M |
| Other current liab | 5.82M | 4.52M | 4.32M | 3.57M | 3.01M |
| Common stock | 0.05M | 0.04M | - | 320.78M | 319.41M |
| Capital stock | - | 0.04M | 342.75M | 320.78M | 319.41M |
| Retained earnings | -402.49M | -353.46M | -311.70M | -276.83M | -243.51M |
| Other liab | - | - | - | 0.48M | - |
| Other assets | - | - | - | 0.59M | 0.44M |
| Cash | 5.80M | 6.92M | 14.58M | 15.46M | 78.24M |
| Cash and equivalents | - | - | - | 15.46M | 78.24M |
| Total current liabilities | 14.06M | 8.33M | 6.45M | 5.93M | 7.32M |
| Current deferred revenue | - | - | - | - | 0.00M |
| Net debt | 52.83M | 34.48M | 25.09M | 6.13M | -73.44M |
| Short term debt | 1.18M | 0.56M | - | 0.27M | 2.60M |
| Short long term debt | - | 0.04M | 0.02M | 0.05M | 2.41M |
| Short long term debt total | 58.63M | 41.40M | - | 21.59M | 4.81M |
| Other stockholder equity | 427.10M | 376.90M | - | 0.79M | 1.03M |
| Property plant equipment | - | - | - | 3.52M | 3.89M |
| Total current assets | 73.16M | 64.47M | 74.37M | 66.59M | 81.10M |
| Long term investments | - | 5.30M | 1.13M | 0.99M | - |
| Net tangible assets | - | - | - | 43.95M | 75.90M |
| Short term investments | 47.43M | 53.75M | 57.74M | 48.07M | - |
| Net receivables | 2.32M | 0.44M | 0.24M | 0.44M | 0.97M |
| Long term debt | - | 40.26M | 39.65M | 19.40M | 0.07M |
| Inventory | 13.80M | 1.39M | - | 2.00M | 1.72M |
| Accounts payable | 7.05M | 3.25M | 1.86M | 2.09M | 1.71M |
| Accumulated other comprehensive income | 0.95M | 0.87M | - | - | - |
| Non currrent assets other | 2.41M | 2.06M | 0.59M | 0.59M | 0.44M |
| Non current assets total | 24.13M | 9.09M | 4.52M | 5.09M | 4.32M |
| Capital lease obligations | - | 1.10M | 1.92M | 2.14M | 2.32M |
| Long term debt total | - | - | - | 19.40M | 0.07M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 11.52M | 1.11M | -8.64M | -49.35M | -0.91M |
| Change to liabilities | - | - | - | 0.73M | 0.72M |
| Total cashflows from investing activities | 8.11M | 1.11M | -8.64M | -49.35M | -0.91M |
| Net borrowings | -0.04M | 0.04M | 20.00M | 17.60M | 20.02M |
| Total cash from financing activities | 48.46M | 32.48M | 40.47M | 17.01M | 95.76M |
| Change to operating activities | - | - | - | 0.42M | 0.39M |
| Net income | -50.46M | -40.80M | -0.04M | -33.09M | -39.84M |
| Change in cash | -1.66M | -7.66M | -0.88M | -62.79M | 72.36M |
| Begin period cash flow | 7.46M | 14.58M | 15.46M | 78.24M | 5.88M |
| End period cash flow | 5.80M | 6.92M | 14.58M | 15.46M | 78.24M |
| Total cash from operating activities | -55.05M | -41.23M | -32.70M | -30.36M | -22.15M |
| Issuance of capital stock | 48.83M | 34.02M | 21.62M | 0.42M | 80.93M |
| Depreciation | 0.42M | 0.97M | 0.00M | 0.65M | 0.38M |
| Other cashflows from investing activities | - | 1.39M | -8.29M | -48.62M | 0.01M |
| Dividends paid | - | - | - | -20.00M | -22.42M |
| Change to inventory | -13.25M | -2.84M | 0.00M | - | - |
| Change to account receivables | -1.94M | -0.21M | 0.09M | - | - |
| Sale purchase of stock | - | 34.51M | 0.05M | -0.21M | -4.90M |
| Other cashflows from financing activities | - | -1.57M | -2.15M | 19.21M | 22.13M |
| Change to netincome | - | - | - | 0.31M | -0.71M |
| Capital expenditures | 3.81M | 0.27M | 0.35M | 0.73M | 0.91M |
| Change in working capital | -9.18M | -2.14M | 0.00M | 1.15M | 1.11M |
| Stock based compensation | 3.05M | 1.74M | 0.00M | - | - |
| Other non cash items | 4.18M | -1.00M | -32.67M | - | - |
| Free cash flow | -58.86M | -41.50M | -33.05M | -0.73M | -0.91M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EBR EBR Systems Inc |
0.01 4.17% |
0.12 | - | - | 14.02 | 0.84 | 4.92 | -3.68 |
| COH Cochlear Ltd |
1.03 0.67% |
155.47 | 68.64 | 27.40 | 4.30 | 5.34 | 3.97 | 28.09 |
| IMR Imricor Medical Systems Inc |
-0.03 2.29% |
1.28 | - | - | 36401.21 | 17.45 | 4019.33 | -2.60 |
| AVR Anteris Technologies Global Corp |
-0.36 4.21% |
8.20 | - | - | 356.02 | 2.19 | 130.34 | -5.20 |
| AVH Avita Medical Inc |
-0.08 1.73% |
4.55 | - | 9.97 | 9.59 | 7.17 | 6.76 | 15.37 |
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization therapy (SOLVE-CRT), an investigational device exemption. The company was incorporated in 2003 and is headquartered in Sunnyvale, California.
480 Oakmead Parkway, Sunnyvale, CA, United States, 94085
408 720 1906
135
| Name | Title | Year Born |
|---|---|---|
| Mr. Allan R. Will | Exec. Chairman | 1954 |
| Mr. John G. McCutcheon | Pres, CEO & Director | 1961 |
| Mr. Frank Hettmann | Chief Financial Officer | NA |
| Mr. Michael Hendricksen | Chief Operating Officer | NA |
| Dr. N. Parker Willis Ph.D. | Chief Technical Officer | NA |
| Mr. Andrew Shute | Sr. VP of Global Field Operations | NA |
| Ms. Madhuri Bhat | Chief Regulatory Officer | NA |
| Dr. Spencer H. Kubo M.D. | Chief Medical Officer | NA |
| Mr. Steve Sandweg | Chief Commercial Officer | NA |
| Mr. John H. Sellers | Sec. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...